Inhibition of USP10 induces degradation of oncogenic FLT3.

[1]  C. Bloomfield,et al.  Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation , 2017, The New England journal of medicine.

[2]  Kay Hofmann,et al.  MINDY-1 Is a Member of an Evolutionarily Conserved and Structurally Distinct New Family of Deubiquitinating Enzymes , 2016, Molecular cell.

[3]  I. de Kouchkovsky,et al.  ‘Acute myeloid leukemia: a comprehensive review and 2016 update' , 2016, Blood Cancer Journal.

[4]  V. Tsui,et al.  Inhibiting the deubiquitinating enzymes (DUBs). , 2015, Journal of medicinal chemistry.

[5]  Karen Cichowski,et al.  Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy , 2015, Cell.

[6]  A. Mesecar,et al.  The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds , 2014, Antiviral Research.

[7]  I. Wertz,et al.  DUBs, the regulation of cell identity and disease. , 2015, The Biochemical journal.

[8]  K. Shokat,et al.  Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy , 2014, eLife.

[9]  A. Jadhav,et al.  Discovery of ML323 as a Novel Inhibitor of the USP1/UAF1 Deubiquitinase Complex , 2014 .

[10]  Satpal Virdee,et al.  Screening of DUB activity and specificity by MALDI-TOF mass spectrometry , 2014, Nature Communications.

[11]  B. Kessler.  Selective and reversible inhibitors of ubiquitin-specific protease 7: a patent evaluation (WO2013030218) , 2014, Expert opinion on therapeutic patents.

[12]  A. Letai,et al.  Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. , 2014, Cancer discovery.

[13]  M. Levis.  FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? , 2013, Hematology. American Society of Hematology. Education Program.

[14]  J. Dou,et al.  USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis , 2013, Cell Death and Disease.

[15]  D. Rigden,et al.  Deubiquitylases from genes to organism. , 2013, Physiological reviews.

[16]  Brunangelo Falini,et al.  Mutational landscape of AML with normal cytogenetics: biological and clinical implications. , 2013, Blood reviews.

[17]  Zhonghan Li,et al.  A kinase inhibitor screen identifies small-molecule enhancers of reprogramming and iPS cell generation , 2012, Nature Communications.

[18]  Parantu K. Shah,et al.  A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. , 2012, Cancer cell.

[19]  V. Battaglia,et al.  Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. , 2012, Chemistry & biology.

[20]  J. Coulson,et al.  Cellular functions of the DUBs , 2012, Journal of Cell Science.

[21]  G. Dianov,et al.  Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. , 2011, Chemistry & biology.

[22]  Chengsheng Zhang,et al.  Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells , 2011, PloS one.

[23]  V. Dixit,et al.  USP1 Deubiquitinates ID Proteins to Preserve a Mesenchymal Stem Cell Program in Osteosarcoma , 2011, Cell.

[24]  H. Ke,et al.  Beclin1 Controls the Levels of p53 by Regulating the Deubiquitination Activity of USP10 and USP13 , 2011, Cell.

[25]  T. Kurosu,et al.  c-Cbl and Cbl-b Ligases Mediate 17-Allylaminodemethoxygeldanamycin-induced Degradation of Autophosphorylated Flt3 Kinase with Internal Tandem Duplication through the Ubiquitin Proteasome Pathway* , 2011, The Journal of Biological Chemistry.

[26]  R. Atwal,et al.  Kinase inhibitors modulate huntingtin cell localization and toxicity. , 2011, Nature chemical biology.

[27]  N. Gray,et al.  Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors , 2010, Molecular Cancer Therapeutics.

[28]  J. Cheville,et al.  USP10 Regulates p53 Localization and Stability by Deubiquitinating p53 , 2010, Cell.

[29]  S. Gygi,et al.  Defining the Human Deubiquitinating Enzyme Interaction Landscape , 2009, Cell.

[30]  N. Gray,et al.  FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. , 2009, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[31]  Chunaram Choudhary,et al.  Flt3-dependent transformation by inactivating c-Cbl mutations in AML. , 2007, Blood.

[32]  A. Hershko,et al.  The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle* , 2005, Cell Death and Differentiation.

[33]  Donna Neuberg,et al.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.

[34]  D. Fushman,et al.  Polyubiquitin chains: polymeric protein signals. , 2004, Current opinion in chemical biology.

[35]  Rob Pieters,et al.  Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. , 2003, Cancer cell.

[36]  Doriano Fabbro,et al.  Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. , 2002, Cancer cell.

[37]  D. Gilliland,et al.  FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. , 2002, Blood.

[38]  D. Birnbaum,et al.  FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates , 1998, Leukemia.

[39]  K. Orita,et al.  Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23) , 1997, Leukemia.

[40]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.